© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Business Strategy
Medicaid Directors Prepare for the End of the Public Health Emergency
June 20, 2022
As many asme 14 million people with Medicaid coverage stand to lose their health insurance when the COVID-19 public health emergency ends.
Digital Therapeutics Emerge Into Uncertain Regulatory, Payment Landscape
June 16, 2022
Legislation that would establish benefit categories for digital therapeutics has been introduced in Congress.
Managing and Retaining Employees During Periods of Disruptive Change
June 07, 2022
To thrive organizations must figure out how to build and maintain a strong culture in an increasingly remote workplace, and implement effective recruitment and retention strategies in an economy where there are fewer workers.
Researchers Identify a Communications Breakdown Over Herceptin Biosimilars
June 06, 2022
If biosimilar acceptance is to grow, it’s going to take a great deal of work to improve the levels of trust between payers, patients, and oncologists.
Review Paper Argues for Broader Use of Riabni, a Rituxan Biosimilar
June 03, 2022
The review, partly funded by Amgen, the maker of Riabni, makes the case for using the biosimilar to Rituxan for all indications of the originator.
New Digital Therapeutics Guide Aims to Bring High Standards, Clarity
June 01, 2022
The guide is designed to help spread best practices and help healthcare decision-makers understand the benefits of digital therapeutics.
Biosimilars Can Help Lower Patient Drug Costs When the Right Teams Come Together: Prime Therapeutics Executive
May 29, 2022
Pharmacy benefit managers can help health plans understand when to best leverage and align to biosimilars and other cost-effective treatments, argues Prime Therapeutics' Kelly McGrail-Pokuta.
Four Ways Medicare Advantage Plans Can Stay Ahead of OIG Denial Concerns
May 20, 2022
A recent HHS Office of Inspector General's report found that Medicare Advantage (MA) plans inappropriately deny prior authorization requests. With MA enrollment growing, scrutiny of MA plans and their utilization management strategies is also likely to grow, according to Alina Czekai, M.P.H., of Cohere Health. Czekai argues that artificial intelligence and machine learning can improve utilization management and prevent inappropriate denials.
Specialty Pharmacy Controls Limit Patient Access, Fein and Long Explain: 2022 Asembia Specialty Pharmacy Summit
May 04, 2022
In their general session, Adam J. Fein, PhD of Drug Channels Institute, and Doug Long of IQVIA reviewed the current specialty pharmacy space, ongoing trends and future expectations.